You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 12, 2025

Details for New Drug Application (NDA): 205017

✉ Email this page to a colleague

« Back to Dashboard

NDA 205017 describes PHENTERMINE HYDROCHLORIDE, which is a drug marketed by Abc Holding, Able, Aurolife Pharma Llc, Barr, Camall, Chartwell Rx, Duramed Pharms Barr, Elite Labs, Elite Labs Inc, Invagen Pharms, Ivax Pharms, Kvk Tech, Lannett, Lannett Co Inc, Nuvo Pharm, Sandoz, Sun Pharm Industries, Teva, Tg United Inc, Upsher Smith Labs, Usl Pharma, Vitarine, Watson Labs, Zydus Pharms, Actavis Elizabeth, Aurobindo Pharma Ltd, Kvk Tech Inc, Novast Labs, Prinston Inc, Puracap Labs Blu, Sandoz Inc, Sun Pharm Inds Inc, Actavis Labs Fl Inc, and Dr Reddys Labs Sa, and is included in eighty-nine NDAs. It is available from twenty-seven suppliers. Additional details are available on the PHENTERMINE HYDROCHLORIDE profile page.

The generic ingredient in PHENTERMINE HYDROCHLORIDE is phentermine hydrochloride; topiramate. There are seventeen drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the phentermine hydrochloride; topiramate profile page.

Summary for 205017

Tradename:	PHENTERMINE HYDROCHLORIDE
Applicant:	Nuvo Pharm
Ingredient:	phentermine hydrochloride
Patents:	0

Pharmacology for NDA: 205017

Physiological Effect	Appetite Suppression Increased Sympathetic Activity

Suppliers and Packaging for NDA: 205017

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
PHENTERMINE HYDROCHLORIDE	phentermine hydrochloride	CAPSULE;ORAL	205017	ANDA	SUNRISE PHARMACEUTICAL, INC.	11534-159	11534-159-01	100 CAPSULE in 1 BOTTLE (11534-159-01)
PHENTERMINE HYDROCHLORIDE	phentermine hydrochloride	CAPSULE;ORAL	205017	ANDA	SUNRISE PHARMACEUTICAL, INC.	11534-159	11534-159-03	1000 CAPSULE in 1 BOTTLE (11534-159-03)

Profile for product number 001

Active Rx/OTC/Discontinued:	RX	Dosage:	CAPSULE;ORAL			Strength	37.5MG
Approval Date:	Sep 25, 2014	TE:	AA	RLD:	No

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.